Johnson & Johnson $JNJ Shares Sold by Keystone Financial Group

Keystone Financial Group trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.6% during the fourth quarter, Holdings Channel reports. The firm owned 48,029 shares of the company’s stock after selling 3,376 shares during the quarter. Johnson & Johnson makes up approximately 0.7% of Keystone Financial Group’s portfolio, making the stock its 29th biggest holding. Keystone Financial Group’s holdings in Johnson & Johnson were worth $9,940,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the company. Midwest Financial Partners Investments Inc. acquired a new position in Johnson & Johnson during the fourth quarter worth $268,000. Van Hulzen Asset Management LLC boosted its holdings in Johnson & Johnson by 1.1% in the fourth quarter. Van Hulzen Asset Management LLC now owns 129,270 shares of the company’s stock valued at $26,752,000 after purchasing an additional 1,378 shares during the period. Goldenstone Wealth Management LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at $1,247,000. FourThought Financial Partners LLC boosted its holdings in Johnson & Johnson by 0.7% in the fourth quarter. FourThought Financial Partners LLC now owns 15,404 shares of the company’s stock valued at $3,188,000 after purchasing an additional 105 shares during the period. Finally, Global Retirement Partners LLC boosted its holdings in Johnson & Johnson by 67.5% in the fourth quarter. Global Retirement Partners LLC now owns 58,519 shares of the company’s stock valued at $12,111,000 after purchasing an additional 23,592 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported that nipocalimab was approved in China, adding another growth opportunity for its immunology portfolio and reinforcing the company’s global pipeline momentum. Reuters article on nipocalimab approval in China
• Positive Sentiment: The company unveiled the Shockwave C2 Aero Coronary IVL Catheter, a next-generation device for treating calcified coronary artery disease, highlighting continued innovation in its MedTech segment. Yahoo Finance article on next-gen catheter
• Positive Sentiment: Johnson & Johnson also announced a collaboration to build a global intelligent operating room network with Abu Dhabi’s Department of Health, which could strengthen its surgical technology and AI strategy over time. Yahoo Finance article on global intelligent OR network
• Neutral Sentiment: Recent commentary from analysts and market outlets continues to frame J&J as a relatively stable large-cap healthcare name with defensive characteristics, which may be helping investors rotate into the stock during market uncertainty. Yahoo Finance article on top stock reports

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $231.69 on Friday. The stock’s 50-day moving average is $234.19 and its two-hundred day moving average is $223.20. The firm has a market cap of $557.73 billion, a price-to-earnings ratio of 26.79, a PEG ratio of 2.25 and a beta of 0.27. Johnson & Johnson has a 1 year low of $149.04 and a 1 year high of $251.71. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Analysts predict that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be given a $1.34 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date is Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.3%. Johnson & Johnson’s payout ratio is presently 60.12%.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent research reports. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a report on Wednesday, April 15th. Barclays lifted their target price on Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, April 15th. Rothschild & Co Redburn lifted their target price on Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a report on Thursday, February 19th. Guggenheim raised their price target on Johnson & Johnson from $244.00 to $266.00 and gave the company a “buy” rating in a research note on Monday, April 20th. Finally, Johnson Rice upgraded Johnson & Johnson from a “hold” rating to an “outperform” rating in a research note on Wednesday, May 13th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $253.04.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.